Abstract Details

Title G2019S mutation and motor complications of levodopa in Parkinson disease

Topic Movement Disorders

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-030

Objective

To assess the impact of the LRRK2-G2019S carrier status on the frequency of dyskinesias and motor fluctuations.

Background

Long-term levodopa treatment is associated with the development of motor complications (motor fluctuations and dyskinesias) in Parkinson´s disease. While phenotype LRRK2-associated, there is paucity of data on the effect of G2019S mutations on complications of dopaminergic therapy.

Design/Methods

The G2019S mutation was screened in Tunisian patients with PD treated with levodopa. The relationship between G2019S mutation carrier status and the prevalence of motor complications (dyskinesias and motor fluctuations) was analyzed. Logistic regression models were used to compare clinical features between the studied group.

Results

The G2019S mutation was screened in 280 Tunisian patients with PD (54% females). Mean age at diagnosis was 62.3 ± 13.2 years. 62 patients developed motor complications.13/62 presented dyskinesia and 49 motor fluctuations. The prevalence of these two complications was non-significantly higher among carriers than non-carriers (27/36) (p >0.05). The mean duration of therapy from levodopa initiation to the development of motor complications was 6±2.4 years for carriers and 4±2.2 years in non-carriers ( p >0.05). G2019S carriers and non-carriers were similar in the duration and dose of levo-dopa treatment.

Conclusions

The LRRK2 G2019S mutation has no effect on the frequency of motor complications in Tunisia levodopa-treated PD patients.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Amina Nasri, MD (Department of Neurology, Razi University Hospital)	Dr. Nasri has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Riadh Gouider, MD, FAAN (Erazi Hospital)	Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Gouider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hikma. The institution of Dr. Gouider has received research support from Clinical Investigation Center. The institution of Dr. Gouider has received research support from Menactrims.
Chokri A. Mhiri, MD (Habib Bourguiba Hospital)	Prof. Mhiri has received personal compensation for serving as an employee of Hikma. Prof. Mhiri has received personal compensation for serving as an employee of Sanofi Genzyme. Prof. Mhiri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Prof. Mhiri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.

��ɫ��

��ɫ��